State of the Art and Perspectives of Gene Therapy in Heart Failure. A Scientific Statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases

Authors:

Abstract
Gene therapy has recently become a reality in the treatment of cardiovascular diseases. Strategies to modulate gene expression using antisense oligonucleotides or small interfering RNA are proving to be safe and effective in the clinic. Adeno-associated viral vector-based gene delivery and CRISPR-Cas9-based genome editing have emerged as efficient strategies for gene delivery and repair in humans. Overall, gene therapy holds the promise not only of expanding current treatment options, but also of intervening in previously untackled causal disease mechanisms with little side effects. This scientific statement provides a comprehensive overview of the various modalities of gene therapy used to treat heart failure and some of its risk factors, and their application in the clinical setting. It discusses specifically the possibilities of gene therapy for hereditary heart diseases and (non)-genetic heart failure. Furthermore, it addresses safety and clinical trial design issues and challenges for future regulatory strategies.
Funding Information
  • Deutsche Forschungsgemeinschaft (SFB-1470-A07)
  • Deutsche Forschungsgemeinschaft (536819681)
  • Deutsche Krebshilfe (70115119)
  • H2020 European Research Council (ERC CoG 101045236)
  • H2020 European Research Council (DISSECT-HF)
  • Deutsche Forschungsgemeinschaft (CRC1366 C07)
  • Deutsche Forschungsgemeinschaft (394046768)
  • European Union's Horizon 2020 research and innovation programme (759248)
  • Health+Life Science Alliance Heidelberg Mannheim GmbH
  • Biotechnology and Biological Sciences Research Council
  • British Heart Foundation (FS/CRTF/21/24175)
  • King's College London BHF Centre of Research Excellence (RE/18/2/34213)
  • European Commission Horizon 2020 Programme (825670)
  • European Commission Horizon 2020 Programme (874764)
  • German Federal Ministry of Education and Research
  • Instituto de Salud Carlos III (CIBERCV CB16/11/00483)
  • Instituto de Salud Carlos III (PI21/00946)
  • Norges Forskningsråd (#309762)
  • National Institutes of Health
  • Deutsches Zentrum für Herz-Kreislaufforschung (81Z0500101 and 81X2500195)
  • Deutsches Zentrum für Herz-Kreislaufforschung (DZHK-BHF: 81X2600522)
  • Bavarian State Ministry of Health (DMB-1805–0001)
  • Bavarian State Ministry of Science and the Arts (1530/89102)
  • German Federal Ministry of Economics and Energy
  • German Federal Ministry of Education and Research (ZF4590201BA8)
  • British Heart Foundation
  • Leducq Foundation for Cardiovascular Research (20CVD01)
  • Leducq Foundation for Cardiovascular Research (18CVD02)
  • Deutsche Forschungsgemeinschaft (471241922)
  • Deutsche Forschungsgemeinschaft (RTG2824-RP4)
  • Deutsche Forschungsgemeinschaft (SFB-1470-B02)
  • Deutsche Forschungsgemeinschaft (SFB1366-C07)
  • Deutsche Forschungsgemeinschaft (394046768)
  • Ministero della Salute (PNRR-MAD-2022-12376632)
  • Ministero della Salute (RF-2016-02362988)
  • European Union Commission's Seventh Framework programme IMI2-CARDIATEAM (N° 821508)
  • Hartstichting (2020-B005)
  • Innovative Medicines Initiative
  • European Union's Horizon 2020 research and innovation programme
  • Deutsche Forschungsgemeinschaft (SFB‐1470‐A07)
  • Deutsche Forschungsgemeinschaft (536819681)
  • Deutsche Krebshilfe (70115119)
  • H2020 European Research Council (ERC CoG 101045236)
  • H2020 European Research Council (DISSECT‐HF)
  • H2020 European Research Council (759248)
  • British Heart Foundation (FS/CRTF/21/24175)
  • Deutsches Zentrum für Herz-Kreislaufforschung
  • Instituto de Salud Carlos III (CIBERCV CB16/11/00483)
  • Instituto de Salud Carlos III (PI21/00946)
  • Norges Forskningsråd (#309762)
  • Ministero della Salute (PNRR‐MAD‐2022‐12376632)
  • Ministero della Salute (RF‐2016‐02362988)

This publication has 172 references indexed in Scilit: